211 related articles for article (PubMed ID: 33372722)
1. Immunodynamics of explanted human tumors for immuno-oncology.
Dubuisson A; Fahrner JE; Goubet AG; Terrisse S; Voisin N; Bayard C; Lofek S; Drubay D; Bredel D; Mouraud S; Susini S; Cogdill A; Rebuffet L; Ballot E; Jacquelot N; Thomas de Montpreville V; Casiraghi O; Radulescu C; Ferlicot S; Figueroa DJ; Yadavilli S; Waight JD; Ballas M; Hoos A; Condamine T; Parier B; Gaudillat C; Routy B; Ghiringhelli F; Derosa L; Breuskin I; Rouanne M; André F; Lebacle C; Baumert H; Wislez M; Fadel E; Cremer I; Albiges L; Geoerger B; Scoazec JY; Loriot Y; Kroemer G; Marabelle A; Bonvalet M; Zitvogel L
EMBO Mol Med; 2021 Jan; 13(1):e12850. PubMed ID: 33372722
[TBL] [Abstract][Full Text] [Related]
2. An In Sitro Assay to Predict Primary Resistance to PD-1 Blockade.
Kobold S
Trends Mol Med; 2021 Apr; 27(4):297-298. PubMed ID: 33518436
[TBL] [Abstract][Full Text] [Related]
3. Personalized Immuno-Oncology.
Jain KK
Med Princ Pract; 2021; 30(1):1-16. PubMed ID: 32841942
[TBL] [Abstract][Full Text] [Related]
4. New Immuno-oncology Targets and Resistance Mechanisms.
Tokaz MC; Baik CS; Houghton AM; Tseng D
Curr Treat Options Oncol; 2022 Sep; 23(9):1201-1218. PubMed ID: 35980521
[TBL] [Abstract][Full Text] [Related]
5. Assessment of IFN-γ and granzyme-B production by in "sitro" technology.
Galassi C; Manic G; Musella M; Sistigu A; Vitale I
Methods Enzymol; 2020; 631():391-414. PubMed ID: 31948559
[TBL] [Abstract][Full Text] [Related]
6. The changing face of clinical trials in the personalized medicine and immuno-oncology era: report from the international congress on clinical trials in Oncology & Hemato-Oncology (ICTO 2017).
Golan T; Milella M; Ackerstein A; Berger R
J Exp Clin Cancer Res; 2017 Dec; 36(1):192. PubMed ID: 29282151
[TBL] [Abstract][Full Text] [Related]
7. Emerging immune checkpoints in the tumor microenvironment: Implications for cancer immunotherapy.
Wei G; Zhang H; Zhao H; Wang J; Wu N; Li L; Wu J; Zhang D
Cancer Lett; 2021 Jul; 511():68-76. PubMed ID: 33957184
[TBL] [Abstract][Full Text] [Related]
8. Leveraging NKG2D Ligands in Immuno-Oncology.
Fuertes MB; Domaica CI; Zwirner NW
Front Immunol; 2021; 12():713158. PubMed ID: 34394116
[TBL] [Abstract][Full Text] [Related]
9. Peripherally-driven myeloid NFkB and IFN/ISG responses predict malignancy risk, survival, and immunotherapy regime in ovarian cancer.
Sprooten J; Vankerckhoven A; Vanmeerbeek I; Borras DM; Berckmans Y; Wouters R; Laureano RS; Baert T; Boon L; Landolfo C; Testa AC; Fischerova D; Van Holsbeke C; Bourne T; Chiappa V; Froyman W; Schols D; Agostinis P; Timmerman D; Tejpar S; Vergote I; Coosemans A; Garg AD
J Immunother Cancer; 2021 Nov; 9(11):. PubMed ID: 34795003
[TBL] [Abstract][Full Text] [Related]
10. In Vivo Modeling of Tumor Heterogeneity for Immuno-Oncology Studies: Failures, Improvements, and Hopes.
DiMarco AV; Maddalo D
Curr Protoc; 2022 Mar; 2(3):e377. PubMed ID: 35255200
[TBL] [Abstract][Full Text] [Related]
11. Review of immune checkpoint inhibitors in immuno-oncology.
Jacob JB; Jacob MK; Parajuli P
Adv Pharmacol; 2021; 91():111-139. PubMed ID: 34099106
[TBL] [Abstract][Full Text] [Related]
12. A first-in-class, non-invasive, immunodynamic biomarker approach for precision immuno-oncology.
Sprooten J; Coosemans A; Garg AD
Oncoimmunology; 2022; 11(1):2024692. PubMed ID: 35036075
[TBL] [Abstract][Full Text] [Related]
13. Cancer immunotherapy efficacy and machine learning.
Fang Y; Chen X; Cao C
Expert Rev Anticancer Ther; 2024; 24(1-2):21-28. PubMed ID: 38288663
[TBL] [Abstract][Full Text] [Related]
14. Pharmacologic Modulation of Human Immunity in the Era of Immuno-oncology: Something Old, Something New.
Bangalore Kumar A; Maus R; Markovic SN
Mayo Clin Proc; 2018 Jul; 93(7):917-936. PubMed ID: 29887221
[TBL] [Abstract][Full Text] [Related]
15. Advances and Challenges in Interventional Immuno-Oncology Locoregional Therapies.
Altun I; Demirlenk YM; Atar D; Cevik E; Gunduz S; Albadawi H; Oklu R
J Vasc Interv Radiol; 2024 Feb; 35(2):164-172. PubMed ID: 38272636
[TBL] [Abstract][Full Text] [Related]
16. Association of a novel 27-gene immuno-oncology assay with efficacy of immune checkpoint inhibitors in advanced non-small cell lung cancer.
Ranganath H; Jain AL; Smith JR; Ryder J; Chaudry A; Miller E; Hare F; Valasareddy P; Seitz RS; Hout DR; Varga MG; Schweitzer BL; Nielsen TJ; Mullins J; Ross DT; Gandara DR; Vidal GA
BMC Cancer; 2022 Apr; 22(1):407. PubMed ID: 35421940
[TBL] [Abstract][Full Text] [Related]
17. The Tumor Microenvironment in the Response to Immune Checkpoint Blockade Therapies.
Petitprez F; Meylan M; de Reyniès A; Sautès-Fridman C; Fridman WH
Front Immunol; 2020; 11():784. PubMed ID: 32457745
[TBL] [Abstract][Full Text] [Related]
18. Refining patient selection for breast cancer immunotherapy: beyond PD-L1.
Kossai M; Radosevic-Robin N; Penault-Llorca F
ESMO Open; 2021 Oct; 6(5):100257. PubMed ID: 34487970
[TBL] [Abstract][Full Text] [Related]
19. Trends and challenges in immuno-oncology trials.
Kiernan B
Drugs Today (Barc); 2016 Jul; 52(7):387-93. PubMed ID: 27540597
[TBL] [Abstract][Full Text] [Related]
20. Sensitizing tumors to anti-PD-1 therapy by promoting NK and CD8+ T cells via pharmacological activation of FOXO3.
Chung YM; Khan PP; Wang H; Tsai WB; Qiao Y; Yu B; Larrick JW; Hu MC
J Immunother Cancer; 2021 Dec; 9(12):. PubMed ID: 34887262
[TBL] [Abstract][Full Text] [Related]
[Next] [New Search]
